DUX4 is a transcription factor required during early embryonic development in placental mammals. In this work, we provide evidence that DUX4 is a co-repressor of nuclear receptors (NRs) of progesterone (PR) and glucocorticoids (GR). The DUX4 C-ter and N-ter regions, including the nuclear localization signals and homeodomain motifs, contribute to the co-repressor activity of DUX4 on PR and GR. Immunoprecipitation studies, using total protein extracts of cells expressing tagged versions of DUX4 and GR, support that these proteins are physically associated. Our studies suggest that DUX4 could modulate gene expression by co-regulating the activity of hormone NRs. This is the first report highlighting a potential endocrine role for DUX4.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/1873-3468.14416 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dynamic interplay of Sp1, YY1, and DUX4 in regulating FRG1 transcription with intricate balance.
Biochim Biophys Acta Mol Basis Dis
December 2024
National Institute of Science Education and Research, School of Biological Sciences, Bhubaneswar, Odisha 752050, India; Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India. Electronic address:
Maintaining precise levels of FRG1 is vital. It's over-expression is tied to muscular dystrophy, while reduced levels are linked to tumorigenesis. Despite extensive efforts to characterize FRG1 expression and downstream molecular signaling, a comprehensive understanding of its regulation has remained elusive.
View Article and Find Full Text PDFSIX transcription factors are necessary for the activation of DUX4 expression in facioscapulohumeral muscular dystrophy.
Skelet Muscle
December 2024
Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Saint Louis, MO, USA.
Article Synopsis
- FSHD is a muscle-wasting disease caused by the misexpression of the DUX4 transcription factor, leading to progressive muscle weakness starting from facial and shoulder muscles and eventually affecting the lower limbs.
- The study utilized siRNAs to investigate the role of SIX family transcription factors in regulating DUX4 expression in patient-derived FSHD muscle cells, revealing that SIX1, SIX2, and SIX4 are essential for DUX4 induction during muscle differentiation.
- Additionally, the research indicated that DUX4 actually downregulates SIX RNA levels, suggesting a negative feedback loop in the regulation of these transcription factors in FSHD contexts.
Germline mutations in SMCHD1, DNMT3B and LRIF1 can cause facioscapulohumeral muscular dystrophy type 2 (FSHD2). FSHD is an epigenetic skeletal muscle disorder in which partial failure in heterochromatinization of the D4Z4 macrosatellite repeat causes spurious expression of the repeat-embedded gene in skeletal muscle, ultimately leading to muscle weakness and wasting. All three proteins play a role in chromatin organization and gene silencing; however, their functional relationship has not been fully elucidated.
View Article and Find Full Text PDFMuscle Proteome Analysis of Facioscapulohumeral Dystrophy Patients Reveals a Metabolic Rewiring Promoting Oxidative/Reductive Stress Contributing to the Loss of Muscle Function.
Antioxidants (Basel)
November 2024
Department of Biomedical Sciences for Health, University of Milan, Via Luigi Mangiagalli 31, 20133 Milan, Italy.
Facioscapulohumeral muscular dystrophy (FSHD) is caused by the epigenetic de-repression of the double homeobox 4 (DUX4) gene, leading to asymmetric muscle weakness and atrophy that begins in the facial and scapular muscles and progresses to the lower limbs. This incurable condition can severely impair muscle function, ultimately resulting in a loss of ambulation. A thorough analysis of molecular factors associated with the varying degrees of muscle impairment in FSHD is still lacking.
View Article and Find Full Text PDFManagement of FSHD symptoms: current assistive technologies and pharmacological approaches.
Disabil Rehabil Assist Technol
November 2024
UCLA Orthopedic Surgery Research Center, Los Angeles, USA.
Background: Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetically linked disorder characterized by the progressive deterioration of muscles controlling facial and scapular movement. The severity and distribution of affected muscle groups vary significantly across patient demographics, necessitating diverse assistive approaches.
Objective: This review aims to evaluate the effectiveness of assistive devices and therapeutic options, including medications and rehabilitative therapies, tailored to specific manifestations of FSHD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!